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Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late 
onset Pompe disease (LOPD) 
 
Aims: Pompe disease is an autosomal recessive 
lysoso- mal storage disorder resulting from deficiency 
of acid a- glucosidase (GAA) enzyme. 
Histopathological hallmarks in skeletal muscle tissue 
are fibre vacuolization and autophagy. Since 2006, 
enzyme replacement therapy (ERT) is the only 
approved treatment with human recombinant GAA 
alglucosidase alfa. We designed a study to examine 
ERT-related skeletal muscle changes   in 18 modestly 
to moderately affected late onset Pompe disease  
(LOPD)  patients  along  with  the    relationship 
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between morphological/biochemical changes and 
clini- cal outcomes. Treatment duration was short-to-
long term. Methods: We examined muscle biopsies 
from 18 LOPD patients at both histopathological and 
biochemi- cal level. All patients underwent two 
muscle biopsies, before and after ERT administration 
respectively. The study is partially retrospective 
because the first biopsies were taken before the study 
was designed, whereas the second  biopsy  was  
always  performed  after at  least   6 months of ERT 
administration. Results: After  ERT,  15 out of 18 
patients showed improved 6-min walking test 
(6MWT; P = 0.0007) and most of them achieved 
respiratory stabilization. Pretreatment muscle biopsies 
disclosed marked histopathological variability, 
ranging from  an  almost  normal  pattern  to  a  severe   
vacuolar 
 
 
 
myopathy. After treatment, we detected 
morphological improvement in 15 patients and 
worsening in three patients. Post-ERT GAA 
enzymatic activity was mildly increased compared 
with pretreatment levels in all patients. Protein levels 
of the mature enzyme increased in   14   of   the   18   
patients   (mean increase = +35%; 
P < 0.05). Additional studies demonstrated an 
improved autophagic flux after ERT in some patients. 
Conclusions: ERT positively modified skeletal muscle 
pathology as well as motor and respiratory outcomes    
in the majority of LOPD patients. 
Keywords: acid alpha-glucosidase deficiency, autophagy, enzyme replacement therapy, Pompe   disease 
 
 
Introduction 
Pompe disease (PD) (glycogen storage disease type 
II; OMIM 232300), is an autosomal recessive disorder 
caused by mutations in the acid a-glucosidase (GAA) 
gene on chromosome 17q25.2–q25.3 [1]. Affected 
indi- viduals accumulate excessive glycogen in the 
lysosomes and cytoplasm of several tissues. There are 
two major clinical manifestations of PD, namely 
infantile (IOPD) and late onset Pompe disease 
(LOPD) forms. LOPD is a slowly progressive 
myopathy involving axial, limb-gir- dle and 
respiratory muscles, often with a variable 
involvement of other organs such as the heart and 
cen- tral nervous system  [2–4]. 
Since 2006, after the promising results from few 
prospective studies on animal models performed 
between the late nineties and the  beginning  of  the 
years 2000 [5–7], the only approved treatment for PD   
is the enzyme replacement therapy (ERT) with 
recombi- nant human GAA (rhGAA; alglucosidase 
alfa, Myozyme®; Sanofi Genzyme, Cambridge, MA, 
USA). In IOPD, early ERT administration reduces 
mortality and disability [8,9], whereas in LOPD 
patients it has shown variable improvement of motor 
performances and respi- ratory  stabilization [10–12]. 
So far, few studies have examined ERT-related 
skele- tal muscle changes in PD patients [13–16]; 
however,  the relationship between the 
morphological/biochemi-  cal changes and the clinical 
outcomes are still    unclear. 
Autophagic mechanisms are implicated in 
multiple human diseases, including PD [17]. 
The autophagic pathway plays a crucial role  in 
skeletal muscle homeostasis, providing a finely tuned 
system which mediates protein degradation and orga- 
nelle removal [18]. Prior data suggest that autophagy 
improves myofiber survival in LOPD by facilitating 
GAA maturation, while its impairment contributes to 
muscle weakness and atrophy   [19]. 
 
 
This retroscpective study analyses skeletal muscle 
tis- sues from 18 LOPD patients before and after ERT 
to survey how ERT can influence skeletal muscle 
pathobi- ology. All the data obtained were further  
correlated  with patient clinical  outcomes. 
 
Methods 
 
Study design 
This study included 18 LOPD patients (8 males, 10 
females) from seven Italian centres. All participants 
provided written informed consent, and the study 
pro- tocol and consent forms were approved by the 
ethics committee of each centre. 
Clinical assessment was performed following estab- 
lished criteria [3,20]. PD diagnosis was confirmed at 
molecular level in all patients [21]. All patients exhib- 
ited axial, limb-girdle and/or respiratory muscles 
impairment at baseline (Tables 1, S1). ERT was 
admin- istered by intravenous infusions of 
alglucosidase alfa (Myozyme®; Sanofi Genzyme) at a 
dose of 20 mg/kg every other week. 
All patients underwent two muscle biopsies 
accord- ing to the following criteria: the first biopsy 
was per- formed for diagnostic purposes before the 
study was designed, namely 6 months – 3 years 
before starting ERT; the second one at least 6 
months after ERT administration (Table 1) and 7–8 
days after the latest ERT infusion. The first muscle 
biopsy was executed in one of the following 
muscles: quadriceps femoris, del- toid or biceps 
brachial. To make results comparable, we decided to 
perform the second one in the same, con- tralateral 
muscle in all patients. 
 
Clinical outcome measures 
From each patient, we obtained demographic and 
clini- cal    data    (Tables 1,    S1).    Patients    were 
regularly 
  
 
 
 
 
 
 
 
 
Table 1. Summary of demographic, molecular and clinical    data of the 18 patients with late onset Pompe disease 
 
 
 
 
 
Age at onset 
 
 
 
 
Age at 
 
 
 
 
Age at ERT 
 
 
 
Mean duration 
of disease at 
 
Timing of the first 
muscle biopsy 
 
Months 
Timing of the 
second muscle 
biopsy 
 
 
Months 
 
Patient   Gender 
GAA mutations 
(Allele  1; Allele 2) Mutation effect 
of symptoms 
(years) 
diagnosis 
(years) 
beginning 
(years) 
ERT start 
(years) 
Muscle 
biopsy 
Age 
(years) 
before 
ERT start 
Age 
(years) 
after 
ERT start 
 
1 M c.-32-13T>G; c.1927G>A p.Gly643Arg 21 31 31 10 Deltoid 31 2 33 25 
2 F c.-32-13T>G; c.1076-1G>C r.1076-79_ 42 51 52 10 Quadriceps 51 2 55 39 
   1195+89ins          
3 M c.-32-13T>G; c.1927G>A p.Gly643Arg 30 66 67 37 Quadriceps 66 8 68 13 
4 F c.-32-13T>G; c.525delT p.Glu176Argfs*45 40 51 51 11 Quadriceps 51 5 53 16 
5 M c.-32-13T>G; c.525delT p.Glu176Argfs*45 65 72 72 7 Biceps 72 3 72 10 
6 M c.-32-13T>G; c.1655T>C p.Leu552Pro 25 56 57 32 Quadriceps 56 13 57 7 
7 F c.-32-13T>G; c.2237G>A p.Trp746* 37 38 40 3 Quadriceps 41 14 41 15 
8 M c.-32-13T>G; c.525delT p.Glu176Argfs*45 16 36 36 20 Quadriceps 36 8 37 8 
9 M c.-32-13T>G; c.525delT p.Glu176Argfs*45 46 48 48 2 Quadriceps 48 5 49 8 
10 M c.-32-13T>G; c.784G>A p.Glu262Lys 50 52 53 3 Quadriceps 52 17 54 8 
11 F c.-32-13T>G; c.525delT p.Glu176Argfs*45 48 54 54 6 Quadriceps 54 1 55 12 
12 F c.-32-13T>G; c.1561G>A p.Glu521Lys 48 58 59 11 Quadriceps 58 7 59 7 
13 M c.-32-13T>G; c.525delT p.Glu176Argfs*45 34 45 45 11 Quadriceps 45 7 46 12 
14 F c.-32-13T>G; c.1927G>A p.Gly643Arg 15 16 16 1 Biceps 16 6 17 7 
15 F c.-32-13T>G; c.2237G>A p.Trp746* 39 40 41 2 Deltoid 40 6 41 8 
16 F c.-32-13T>G; c.1465G>A p.Asp489Asn 37 49 50 13 Quadriceps 49 14 54 46 
17 F c.-32-13T>G; c.2331+1 
G>A 
Loss  of transcript 30 39 41 11 Quadriceps 39 22 45 57 
18 F c.-32-13T>G; c.1465G>A p.Asp489Asn 50 53 56 6 Biceps 53 31 57 8 
Mean    36.8 46.9 47.6 10.9  47.1 8.9 49.1 17.0 
Mean 
(SD) 
   13.2 13.1 13.2 10.2  13.0 8.1 13.1 14.9 
GAA, acid alpha-glucosidase; ERT, enzyme replacement therapy. 
 
  
 
 
monitored and evaluated following previously 
reported protocols [20,22]. Forced vital capacity 
(FVC) was spiro- metrically assessed in the sitting 
position, and expressed as a percentage of the 
predicted value. Motor function was assessed by the 
6-min walking test (6MWT). 
 
Morphological study 
All samples were analysed by operators from two refer- 
ring centres: Foundation IRCCS Ca0 Granda 
University of Milan and Institute C. Besta, Milan. 
Samples were both fixed in 2.5% glutaraldehyde (pH 
7.4), and frozen in liq- uid nitrogen, and processed using  
standard  techniques  [23]. Three different blinded 
operators evaluated each biopsy following the protocol 
by Peverelli et al. [24]. For each biopsy, four digitized 
non-overlapping consecutive pictures were taken of four  
randomly  selected  areas  of the same cryostatic section 
stained with GT, AP and Per- iodic Acid-Schiff (PAS). 
Pictures were taken at 9 20 magnification using a 
camera-equipped Leica  DC200 optic microscope 
(Leica Microsystems Srl, Milano, Italy) and then 
examined using image analyzer software IM50 (Leica 
Microsystems Srl, Milano, Italy). In order to iden- tify 
and assess the effect of ERT on vacuolated fibres, We 
established a rigorous protocol for classification and 
developed a scoring system to define treatment 
response.   In detail, for each biopsy, total number of 
fibres, percent- age of vacuolated fibres and percent 
coefficient of varia- tion (CV) were calculated. By GT 
and AP staining, we created a four-point graded scale to 
classify vacuolated fibres according to vacuole number  
and  size  (from  mild to very severe vacuolation) 
(Figure S1A). The  percentage of different types of 
vacuolated fibres was assessed in pre- and post-ERT 
biopsies and a relative change ≥20% (>3 standard 
deviation of the CV) served as the standard cri- terion to 
determine relevant improvement or worsening, using 
similar criteria described for the evaluation of dif- ferent 
biomarkers. [25,26]. Furthermore, a vacuolation 
weighted delta (VWD) score, scoring the changes across 
the four-point graded scale between pre- and post-ERT 
biopsies, was created to determine the ‘Overall Vacuola- 
tion Response’ to the ERT and used for the analysis 
(Fig- ure S1B). For PAS staining intensity, we used a 
scale ranging from + (mild) to +++ (severe) (Table S2) 
[27] in both cryostatic and semithin sections. We also 
analysed   the following histological features: fibre size 
variability, fibre atrophy and hypertrophy, the  presence  
of  angu- lated   fibres   and   fibre   splitting,   increased   
connective 
 
tissue, fibre necrosis, the presence of internal nuclei 
(Table S3) as previously reported [24,27]. 
 
Morphometric analysis 
For morphometric analysis, ATPase fibre-type  
staining at pH 4.3, 4.6 and 9.4 was performed on 
Optimum Cutting Temperature (OCT)-embedded 
frozen tissue sec- tions following standardized 
protocols. Using four con- secutive microphotographs 
of sections stained for ATPase at pH 9.4, we 
calculated the vacuolated fibre percentage for each 
fibre typology (Table S4). 
 
 
Determination of acid alpha-glucosidase activity in 
muscle 
For biochemical analysis, muscle specimens were 
immediately  frozen  in  liquid  nitrogen  and  stored    
at 
—80°C. Acid alpha-glucosidase deficiency was mea- 
sured before and after ERT by fluorometric 
determina- tion of enzyme activity [28]. 
 
Protein studies 
Protein samples obtained from fresh-frozen muscle 
biop- sies were immunoblotted as previously 
described [29], Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a loading 
control. We performed densitomet- ric quantification 
from multiple gels for each experiment using ImageJ 
software (US National Institutes of Health). 
Antibodies used for western blot analysis included 
pri- mary antibody to microtubule-associated protein 
1 light chain 3 b (LC3II) (Sigma-Aldrich, S.r.l. Milan, 
Italy), antibody to SQSTM1 (GSQSTM1-C) (Progen 
Biotechnik GmbH, Heidelberg, Germany), antibody 
to GAA (Sanofi Genzyme, Cambridge, MA, USA), 
antibody to GAPDH (Abcam, Cambridge, United 
Kingdom), and Horseradish Peroxidase (HRP)-
labelled secondary anti-mouse, anti- rabbit (GE 
Healthcare, Milan, Italy), and anti-guinea pig 
antibodies (Sigma-Aldrich). 
 
Statistical analysis 
Statistical analyses were performed using Stata soft-  
ware (Version 13.0; Stata Corp LLC, Texas, USA) 
and SAS (version 9.0; SAS Institute Inc., Cary, NC, 
USA). 
Data were assessed for equality of variance and 
distri- bution.  Descriptive  statistics  with  means  and 
medians, 
 
 
 
 
 
as appropriate, and proportions were used to describe 
continuous and categorical variables. Paired t-tests were 
used to assess changes in Body Mass Index (BMI), FVC 
and 6MWT. For statistical comparison of non-normally 
distributed continuous variables, we used the Mann– 
Whitney U test in case of two groups and the Kruskal– 
Wallis test in case of three or more groups. Correlation 
analyses were performed by  means  of  the  
nonparamet- ric Spearman rank correlation test. The 
association  between categorical variables was evaluated 
using the Fisher’s exact test. All statistical tests were 
two-tailed and a P value  <  0.05 was considered    
significant. 
 
Results 
 
Description of population and clinical outcomes 
before and after ERT 
In our cohort (n = 18), 55.6% (10) of the subjects 
were women, the average patient age at onset of 
symptoms was 37.39 T 13.1 years, while the 
average patient age at diagnosis was 47.5 T 13 
years, with a median diag- nostic delay of 9 years 
(range = 1–36). The mean BMI was 23.13  T 3.75. 
Seventeen patients were fully ambulant and one 
used a walker before ERT. The median walking 
distance  was 
393.9 m (T127.0) and the mean FVC in the sitting 
position was 81.7% (T23.2). Two (11%) patients 
required ventilatory support for less than 12 h a day 
before starting ERT. 
ERT treatment was initiated in all patients at  vari-  
able ages after symptoms onset (range = 1–37 years)  
and about 1  year (0–3) after  diagnosis. 
After ERT, 15 patients improved in 6MWT 
(mean distance walked 448.6 T 127.1 m, P = 
0.0007) while no significant changes were observed 
in FVC (mean post-treatment 80.4T22.2%, P = 
0.79). Six patients (in addition to the initial two) 
needed the respiratory sup- port (four for <12 
h/day, two for longer). 
BMI   did   not   change    after    treatment    
(mean = 23.19 T 3.76, P  = 0.71; Table 1,    S1). 
 
Morphological evaluation of muscle biopsies 
before and after ERT 
Morphological findings resulted from the 
observations   of three different blinded operators 
from the two refer- ring centres as described (see 
Methods). 
 
Pretreatment muscle biopsies showed marked 
histopathological variability, ranging from an almost 
normal morphology to a severe  vacuolar  myopathy. 
The most common abnormalities included muscle 
fibres with PAS-positive vacuoles of varying number 
and size (Figure 1) and a glycogen storage. The 
comparison of pre- and post-ERT vacuolated fibres of 
the 18 patients showed morphological improvement 
in  15  patients, and worsening in 3 patients 
according to the  VWD  score (Figures 2, S1B). In 
particular, after ERT, in 15 patients, we observed a 
significant reduction in the pro- portion of vacuolated 
fibres of grade + (mild) and ++ (moderate) compared 
to fibres of grade  +++ (severe) and ++++ (very 
severe) (67% vs. 39%, P = 0.0275). 
The 15 muscle biopsies showing vacuolated fibre 
reduction also showed a relevant glycogen 
reduction, whereas the three worsened biopsies 
showed glycogen increase. Notably, we observed 
that small PAS-positive accumulations disappeared 
in all post-treatment biop- sies, whereas large PAS-
positive collections were unchanged or increased. 
These data were particularly evident at PAS 
staining of frozen and semithin sections evaluation 
(Figure 1, Table S2). 
The histochemical acid phosphatase activity was 
abnormal in all patients and  paralleled  both  number  
and size of vacuoles along with a variable intracyto- 
plasmic activity. 
Pretreatment biopsies showed internal nuclei in 
17 patients and large fibre size variability in most 
sam- ples, with coexistence of atrophic and 
hypertrophic fibres. Scattered angulated fibres were 
seen in muscle biopsies from 16 patients. These 
latter aspects remained basically unchanged in post-
treatment biop- sies (Table S3). 
 
Morphometric analysis 
In the first biopsy, 15 patients showed nonselective 
involvement of muscle fibre types; a slight 
prevalence of type 1 vacuolated fibres was present 
in seven patients, whereas type 2 vacuolated fibres 
were some- what predominant in two patients. In 
addition, patients 7 and 17 showed selective 
vacuolization in type 1 mus- cle fibres, while 
patient 14 revealed only vacuolated fibres of type 2. 
These patterns remained nearly unchanged in post-
treatment biopsies, except for patient 16, where the 
muscle fibre percentages reversed (Table S4). 
  
 
 
 
Figure 1. PAS staining in muscle biopsies before and after ERT. Representative pictures of muscle PAS staining (example of pt 
number 14). (A–D) PAS staining on semithin sections; (E,F) PAS staining on frozen sections. Upper panel: pretreatment muscle 
biopsy, lower panel: post-treatment muscle biopsy. Small PAS-positive accumulations (A) disappear in post-treatment biopsies (B) 
whereas the large PAS-positive collections (C) are unchanged or increased (D). PAS staining shows an important glycogen 
accumulation in pretreatment muscle tissue (E), which is reduced after therapy (F). Original magnification: A,C: 9 400; B,D: 9 
1000; E,F: 9 250. 
 
Molecular characterization, muscle acid 
alpha- glucosidase activity and protein 
levels 
All patients harboured the heterozygous IVS1-13T>G 
mutation, affecting exon 2 within GAA transcript. The 
second allele carried truncating and out-of-frame 
muta- tions (10/18) or known missense variants 
(8/18). Six patients (33%) harboured the c.525delT 
microdeletion, the second most common molecular 
defect. Before ERT, mean residual activity of acid 
alpha-glucosidase in muscles was 8.45 T 3.22 
pmol/min/mg protein (refer- ence value: 113 T 41 
pmol/min/mg protein)   (Fig-  ure 3B). The lowest 
residual activity levels were observed in patients 
harbouring a non-sense mutation   or variant resulting 
in amino acid change near the enzyme’s catalytic site. 
The mean residual activity sig- nificantly improved 
after ERT (11.31 T 2.87 pmol/ min/mg, P < 0.05) 
(Figure 3B). The increased enzyme activity greatly 
varied, ranging from +7.7% in patient 
6 to +202.6% in patient 16. Patients 10 and  12  
showed the highest GAA activity levels both before 
and after ERT (Figure 3A). 
We also evaluated GAA protein level by western 
blot analysis.  Muscle  specimens  displayed  a  
maximum  of 
three major   bands   corresponding   to   preprotein  
(110 kDa) and mature forms  of  the  enzyme  (76  
and 70 kDa). The 110-kDa band was detected in 
patients harbouring missense mutations, particularly 
in patients with defects known to impair GAA 
enzyme physiologi- cal maturation (patient 12 with 
pGlu521Lys, and patient  6  with pLeu552Pro). 
After GAPDH correction, densitometric analysis 
revealed increased (>35%) GAA mature forms in the 
second biopsies of 14 patients, with five of them 
show- ing a doubled GAA signal intensity post-ERT. 
Protein levels decreased in the remaining  four  
subjects  (Fig- ure 3C). The ratio between mature  
and preprotein forms (where observed) was 
unchanged  before  and after ERT in six subjects and 
modestly increased after ERT in the remaining 
patients. Overall, after ERT, we observed a positive 
correlation between mature protein levels and residual 
alpha glucosidase activity in most patients (Figure 
3D). 
ERT treatment preserved this correlation and 
resulted in a modest increase of active acid alpha-
glucosidase enzyme. There was a positive correlation 
at both first  (R = 0.74,     P = 0.0005)     and     
second     (R = 0.55, 
P = 0.022) biopsy (Figure 3D). 
(A) (C) (E) 
(B) (D) (F) 
 
 
 
 
 
 
 
Figure 2. Morphological evaluation of muscle biopsies before and after ERT. (A) Vacuolation weighted delta (VWD) score of our 
population. (B) Three-dimensional representation of the VWD score of our  population. 
 
Analysis of the autophagic  pathways 
To determine whether ERT affected autophagy, we 
monitored the LC3 lipidation level as readout of 
autophagosome and the expression of the autophagy 
substrate, p62/SQSTM1, as an index of lysosomal- 
dependent clearance. 
LC3II analyses revealed heterogeneity. Indeed, 
ERT determined LC3II increase in five patients, no 
changes in three patients and a reduction  in  five  
patients (Figure 4A). 
Post-treatment biopsies also showed decreased p62/ 
SQSTM1 protein in eight patients and an 
accumulation in five patients (Figure 4B). Three of 
these latter patients (patients 8, 13, and 16) also 
displayed LC3II accumulation. 
 
Discussion 
ERT with rhGAA is currently the only therapy  
approved for PD. The beneficial effects in improving 
survival, maintaining motor functions over time as   
well 
  
 
 
 
 
Figure 3.  Biochemical analysis in muscle biopsies before and after ERT. (A) Quantification of residual acid alpha-glucosidase activity 
in     late onset Pompe disease patients before (blue) and after (red) ERT administration. (B) Mean values of the two series (P  <  0.01). 
Values       are expressed as pmoles product formed per min and per mg protein. (C) Densitometric analysis of GAA levels from 
different blots. 
Expression of immature (yellow) and mature (blue) GAA forms (110 and 95 kDa: inactive precursor and immature forms, 
respectively;     76 and 70 kDa: mature lysosomal forms) in patients compared to untreated biopsies. (D) Correlation between mature 
GAA protein levels (x-axis, arbitrary units from densitometric analysis) and residual acid alpha-glucosidase activity (y-axis, values 
expressed as pmol/min/    mg) in muscle biopsies before (red circles) and after (blue squares) ERT  administration. 
 
as preventing severe deterioration or stabilize 
respira- tory parameters have been demonstrated in 
LOPD patients [3,10–12]. 
We examined skeletal muscle biopsies from 18 
LOPD patients before and after ERT treatment 
lasting from 7 to 57 months. The second biopsy 
was performed after at least 6 months of ERT 
administration (Table 1) and 7–8 days after the 
latest ERT infusion. Our population is 
heterogeneous because patients were recruited 
retro- spectively and therefore underwent the first 
muscle biopsy, taken for diagnostic purposes, with 
variable timing before the study was designed. This 
aspect, which would represent a bias in case of a 
purely exper- imental study, turned into a useful 
instrument in our study because it gave us the 
opportunity to examine ERT effects also in subjects 
(and skeletal muscles) who were treated for a long 
time and/or who started ERT several months/years 
after the diagnosis was made. 
Our patients showed significant post-treatment 
improvement at 6MWT. The majority of them 
obtained respiratory stabilization, although six 
patients, in addi- tion to the initial two, required 
respiratory  support (four for  <12 h/day,  two  for  
a  longer  period) (Table S1). 
In pretreatment muscle biopsies, the most 
common histological abnormalities were vacuolated 
fibres, accu- mulation of PAS-positive material 
(glycogen), and increased acid phosphatase activity. 
Comparison of glycogen content and vacuole 
number between pre- and post-treatment biopsies 
revealed improvement in 15 patients, and worsening 
in three patients. 
The best outcome in second biopsies was observed 
when the architecture of the skeletal muscle fibres 
was not so severely impaired in pretreatment biopsy,  
namely when the vacuoles were of a minor  degree.  
Also,  we   noticed   the   disappearance   of  small 
PAS- 
 
 
 
 
 
 
 
Figure 4. Densitometric analysis of LC3II, and p62/SQSTM1. Densitometric analysis of (A) LC3II, and (B) p62/SQSTM1 
normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Different blots evaluated protein expression in 13 patients 
compared to untreated biopsies. 
 
positive accumulations in post-treated biopsies, 
whereas larger PAS-positive collections were 
almost unchanged (Figure 1). 
Importantly, we demonstrated a differential effect 
of the ERT therapy on the vacuolated fibres. 
Specifically, a significantly higher proportion of 
grade + (mild) and ++ (moderate) vacuolated fibres 
improved as compared to grade +++ (severe) and 
++++ (very severe) vacuolated fibres (67% vs. 39%, P 
= 0.0275). These findings suggest that the ERT 
therapy produces a greater beneficial effect on the less 
affected fibres, thus supporting the idea that the 
treatment is most effective when initiated in early 
stages of PD, before severe and very severe 
vacuolated fibres appear and become too widespread. 
These conclu- sions resulted from the observations of 
three different blinded operators from the two 
referring centres. 
These data are in agreement with those of van der 
Ploeg et al.[14], who show a beneficial ERT effect on 
small glycogen accumulations, whereas the larger 
glycogen pools, which are the hallmark of the most 
damaged fibres, remained refractory to treatment.  
These morphological considerations may help 
clinicians assess  the  most  appropriate  timing  to  
start treatment. 
Moreover, lack of progression of the disease might 
be an important factor as well as the   improvement. 
Studies in knockout mice show that autophagic vac- 
uole accumulation in skeletal muscle is mainly 
restricted to type 2 fibres, and that type  1  fibres 
respond better to ERT than type 2 fibres [7,30], most 
likely because muscles with predominantly type 1 
(slow-twitch) fibres, namely soleus and 
cardiomyocytes, have a higher capillary density [31]. 
Conversely, autop- hagic accumulation in humans 
involves  both  type  1  and type 2 muscle fibres  
[32,33]. 
Among our 18 patients, before ERT, nine muscle 
samples showed prevalent involvement of type 1 mus- 
cle fibres, whereas three samples mainly showed 
vacuo- lation in type 2 fibres. These features  were 
unchanged in post-treatment biopsies. The other six 
specimens showed a non-selective involvement of 
muscle fibre types. We concluded that the vacuolated 
fibre typology does not correlate with disease severity 
nor does it pre- dict morphologic evolution, at least in 
the skeletal mus- cles we examined. Indeed, vacuole 
fibre type localization changed in a few treated 
subjects indepen- dently on morphological outcomes 
(Table  S4). 
 . 
 
 
 
 
Scattered angulated fibres were seen in muscle 
biopsies from 16 patients and we found no 
modifications in post- treatment biopsies (Table S3). 
The neurogenic origin of the scattered angulated 
fibres we found cannot be excluded and 
Electromyography (EMG) findings (coexis- tence of 
myopathic and mild to moderate neurogenic signs) 
are compatible with this hypothesis in some of our 
patients. Indeed, as already suggested by other 
authors [34], glycogen storage in muscle-
innervating structures may account for the presence 
of neurogenic signs in muscle biopsies. 
Post-treatment muscle biopsies worsened in 
patients 16, 17 and 18. In patients 16 and 17, very 
long time had passed between disease onset and 
ERT start, whereas the delay was shorter in patient 
18. The diag- nostic delay may have negatively 
influenced the ability of ERT to restore or limit 
muscle alterations, especially when large vacuoles 
were present. Also, patient 18 underwent second 
muscle biopsy after 8 months of ERT, whereas pts 
16 and 17 after 46 and 57 months respectively. In 
the latter, we can also postulate that the bioptic 
worsening has followed an initial improve- ment. 
These observations indicate that bioptic outcome 
and ERT duration do not easily correlate. Despite 
the histological worsening, all these patients 
improved at 6MWT with minimal changes in FVC. 
Thus, we may speculate that the contractile force of 
nondegenerated muscle fibres improves, despite 
worsening of some mor- phological parameters in 
selected muscle areas. 
The opportunity to study muscle tissue before  and 
after ERT allowed us to also perform biochemical 
anal- ysis in 17 patients. All of them showed 
moderately increased GAA enzymatic activity in 
post-treatment skeletal muscles, in accordance with a 
slightly  increased level (>35%) of GAA mature 
forms in 14 patients. These differences were not 
related to specific patient genotypes. ERT is intended 
to increase the residual enzyme activity enough to 
induce measurable clinical improvement. While IOPD 
is always associated with complete or nearly-
complete deficiency of GAA enzyme activity (<1% of 
control values), LOPD is asso- ciated with reduced 
enzyme activity ranging from 1%   to 30% of normal 
[35,36]. Notably, patients carrying  the same 
enzymatic activity may present different clini- cal 
patterns. We may postulate the existence of a speci- 
fic patient-related threshold of enzymatic activity 
below which a presymptomatic/oligosymptomatic 
patient becomes  overtly  symptomatic  [37].  So,  
subjects  with 
 
residual activity just below this threshold may show 
clinical improvement with only a slight increase in 
enzymatic activity. 
The autophagic pathway plays a crucial role in 
skeletal muscle homoeostasis, providing a finely 
tuned system to mediate protein degradation and 
organelle removal [18]. In PD, autophagy 
impairment con- tributes to muscle pathology in the 
animal model (GAA-ko) [17] and in human 
muscles [19]. To deter- mine whether autophagy 
was influenced by ERT, we monitored LC3 
lipidation levels as a reflection of autophagosomes, 
and the expression of the autophagy substrate 
p62/SQSTM1 as an index of lysosomal-depen- dent 
clearance. 
Since PD is characterized by autophagosome build- 
up, an increase of LC3II may reflect impaired 
autophagosome degradation as well as an induction of 
autophagosome biogenesis. A reduction of the LC3II 
band after ERT, could indicate increased autophago- 
some clearance. LC3II analysis revealed a certain 
heterogeneity, with ERT leading to increased LC3II 
in five patients, no change in three patients, and 
reduced LC3II in five patients. 
To better understand whether autophagy was 
impaired or activated, we monitored expression of 
the autophagy substrate p62/SQSTM1. 
Interestingly, ERT led to decreased p62/SQSTM1 
protein in eight patients and to p62/SQSTM1 
accumulation in five patients. Three of the five 
patients with p62/SQSTM1 accumula- tion (patients 
8, 13 and 16) also displayed LC3II accu- mulation, 
suggesting that autophagy was not reactivated by 
ERT. The decreased p62 in eight patients suggested 
autophagy system improvement after ERT. These 
findings are mostly in agreement with previous 
studies in animal models that have shown a clear 
cor- relation between autophagosome accumulation 
and ERT ineffectiveness. Importantly, ERT requires 
a func- tional cell-trafficking system to allow 
delivery of recom- binant enzyme to the lysosomes. 
The comparison between untreated and treated 
biop- sies in this group of patients represents an 
important contribution to the understanding the role 
of autophagy and the effects of ERT on muscle 
tissue. However, our results were discordant in 
some patients; for example, the post-treatment 
biopsy from patient 8 showed wors- ened features 
compared to the pre-treatment biopsy. In detail, 
western blot analysis showed an accumulation of 
LC3II  and  P62  in  the  post-treatment  biopsy.  It   
is 
 
 
 
 
 
difficult to understand how these negative features 
cor- relate with co-existing increased GAA mature-
form, decreased immature form, and higher GAA 
enzymatic activity level. Similarly, in patient 16, the 
post-treat- ment biopsy was morphologically worse 
than the pre- treatment one and we observed increase 
in both the mature and the immature GAA forms, 
with accumula- tions of both LC3II and P62. Despite 
these data, this patient showed the highest level of 
enzymatic  activity. 
In summary, our data showed that ERT positively 
modifies skeletal muscle pathology, at least in 
modestly to moderately affected LOPD patients. 
These results are clearer in the earlier phases of  ERT  
administration, with a variable stability in the 
following years. Muscle biopsy improvement was 
evaluated in terms of reduced PAS-staining and 
disappearance of less severe vacuoles in post-
treatment biopsies, both of which suggest a direct 
effect on reduction in the lysosomal glycogen pool. 
The evidence of treatment efficacy is further sup- 
ported by biochemical findings showing mildly 
increased GAA enzymatic activity in all post-
treatment muscle biopsies. Moreover, in 14 patients, 
western blot analysis demonstrated the conversion of 
the 110-kDa precursor to mature 76/70-kDa a-
glucosidase, strongly suggesting that the enzyme is 
targeted to lysosomes, where this proteolytic 
processing occurs [38]. Finally, most of these patients 
showed post-ERT improvement   of autophagic flux, 
which contributes to GAA process- ing and 
maturation. Overall, we assessed the clinical, 
morphological and biochemical effects of ERT on 
skele- tal muscle tissue in a group of LOPD  patients. 
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Figure S1. (A) Muscle biopsy evaluation. Two muscle 
biopsies, before and after ERT, from 18 patients were 
analysed. Vacuolated fibres were classified according 
to a four-point graded scale considering both the 
number and the size of vacuoles. Original 
magnification:    4009. 
+, normal or mild, fibres containing few and small 
vac- uoles; ++, moderate, fibres with more numerous 
small vacuoles and few large vacuoles; +++, severe, 
fibres with large vacuoles; ++++, very severe, fibres 
with large vac- uoles that replaced most of the 
sarcoplasm. Mean values were obtained by each 
operator (three different opera- tors) for each biopsy 
and the final value, expressed in percentage, 
represents the mean of each operator mean value. (B) 
Vacuolation weighted delta (VWD) score chart for the 
assessment of response to the ERT in patients with 
Pompe disease according to their vacuolated fibres 
characteristics. Vacuolated fibres were classified 
accord- ing to a four-point graded scale considering 
both the number and the size of vacuoles. Pre- and 
post-ERT biop- sies were scored according to these 
criteria and a relative change ≥20% between pre- and 
post-ERT biopsies served as the criterion standard to 
determine relevant improve- ment or worsening. 
Vacuolation reduction ≥20% (opti- mal treatment 
response) was assigned a score of 0 point. The lack of 
changes in vacuolation (suboptimal treat- ment 
response) was given 0.5 point. Lastly, in line with a 
more severe degree of impairment of muscle fibres a 
dif- ferent  weight  was  assigned  to  vacuolation     
increase 
≥20% depending on the different vacuolated fibres 
char- acteristics, with a minimum score of 1 to a 
maximum  of 
2. The VWD scores range from 1 to 8, with scores of 
≤4 indicating an overall improvement/unmodified 
condi- tion, and >4 indicating an overall worsening. 
aWe chose to add plus 1 for simple mathematical 
reasons. 
 
 
 
 
 
Table S1. Clinical features of the 18 patients with 
late onset Pompe disease. 
Table S2. PAS staining evaluation in each biopsy.   
Table S3. Histopathological features in pre- and 
post- ERT muscle biopsies of the 18 patients with 
late onset Pompe disease. 
 
Table S4. Percentage of vacuolated fibres (type 1 or 
type 2) in each biopsy. 
 
